Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance

Heron Therapeutics IncTrade
Vanguard S&P 500 Growth Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Heron Therapeutics Inc trades at $0.34 (market cap $61.47M), while Vanguard S&P 500 Growth Index Fund ETF trades at $85.15. The key difference: Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HRTXVOOG
Market Cap
$61.47M
Sector
HealthBroad Market / Factor
52-Week High
$1.49$85.42
52-Week Low
$0.32$65.32
Enterprise Value
$168.21M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.

The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.

Vanguard S&P 500 Growth Index Fund ETF

VOOG trades at $85.155, down 0.05% today, with a bullish technical signal driven by moving averages and strong trend momentum (ADX). The ETF recently hit a 52-week high, reflecting positive market sentiment. Recent news highlights institutional buying, such as Apella Capital increasing holdings by 463.2% in Q2 2026 (Defense World, August 7, 2026).

Outlook remains favorable due to growth stock exposure and low expense ratio (0.07%), but risks include tech concentration and overbought RSI levels. Analysts view VOOG as a core growth holding, though volatility from sector shifts poses a near-term challenge.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Vanguard S&P 500 Growth Index Fund ETF

VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.

Read more on VOOG